Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Endocrinol Metab ; 96(5): 1368-76, 2011 May.
Article in English | MEDLINE | ID: mdl-21346067

ABSTRACT

BACKGROUND: Recombinant human TSH (rhTSH) can be used to enhance (131)I therapy for shrinkage of multinodular goiter (MG). OBJECTIVE, DESIGN, AND SETTING: The objective of the study was to compare the efficacy and safety of 0.01 and 0.03 mg modified-release (MR) rhTSH as an adjuvant to (131)I therapy, vs. (131)I alone, in a randomized, placebo-controlled, international, multicenter study. PATIENTS AND INTERVENTION: Ninety-five patients (57.2 ± 9.6 yr old, 85% females, 83% Caucasians) with MG (median size 96.0, range 31.9-242.2 ml) were randomized to receive placebo (group A, n = 32), MRrhTSH 0.01 mg (group B, n = 30), or MRrhTSH 0.03 mg (group C, n = 33) 24 h before a calculated activity of (131)I. MAIN OUTCOME MEASURES: The primary end point was a change in thyroid volume (by computerized tomography scan, at 6 months). Secondary end points were the smallest cross-sectional area of the trachea; thyroid function tests; Thyroid Quality of Life Questionnaire; electrocardiogram; and hyperthyroid symptom scale. RESULTS: Thyroid volume decreased significantly in all groups. The reduction was comparable in groups A and B (23.1 ± 8.8 and 23.3 ± 16.5%, respectively; P = 0.95). In group C, the reduction (32.9 ± 20.7%) was more pronounced than in groups A (P = 0.03) and B. The smallest cross-sectional area of the trachea increased in all groups: 3.8 ± 2.9% in A, 4.8 ± 3.3% in B, and 10.2 ± 33.2% in C, with no significant difference among the groups. Goiter-related symptoms were effectively reduced and there were no major safety concerns. CONCLUSION: In this dose-selection study, 0.03 mg MRrhTSH was the most efficacious dose as an adjuvant to (131)I therapy of MG. It was well tolerated and significantly augmented the effect of (131)I therapy in the short term. Larger studies with long-term follow-up are warranted.


Subject(s)
Goiter, Nodular/therapy , Thyrotropin/therapeutic use , Adult , Aged , Aged, 80 and over , Anatomy, Cross-Sectional , Combined Modality Therapy , Delayed-Action Preparations , Double-Blind Method , Female , Goiter, Nodular/drug therapy , Goiter, Nodular/radiotherapy , Humans , Iodine Radioisotopes/pharmacokinetics , Iodine Radioisotopes/therapeutic use , Male , Middle Aged , Quality of Life , Recombinant Proteins/therapeutic use , Thyroid Function Tests , Thyroid Hormones/blood , Thyroidectomy , Thyrotropin/administration & dosage , Thyrotropin/adverse effects , Trachea/anatomy & histology
2.
J Endocrinol Invest ; 34(3): e52-7, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20834199

ABSTRACT

BACKGROUND: Radioiodine (131I) therapy is widely used for treatment of non-toxic goiters. A limitation for this treatment is a low thyroid radioiodine uptake (RAIU), often encountered in these patients. AIM: To estimate the impact of various factors on the thyroid RAIU. METHODS: We examined prospectively 170 patients (146 females; age range: 22-87 yrs) with nodular goiter (median 64 ml, range: 20-464 ml) selected for 131I therapy. Serum TSH was sub-normal in 42.4%. None were treated with anti-thyroid drugs. The thyroid RAIU was determined at 24h and 96 h. The goiter volume was measured by ultrasound (no.=127), or by magnetic resonance imaging (no.=43). RESULTS: The 24h and the 96 h RAIU were 34.2 ± 9.8(SD)% (range: 11.4-66.0%) and 34.0 ± 10.0% (range: 10.5-60.9%), respectively. Sixty-one patients had a 24h RAIU <30% and these individuals were older than patients with a 24h RAIU ≥ 30% (median 58 vs 51 yrs, p=0.02). These two subgroups did not differ significantly in other variables. Overall, the 24h RAIU was positively correlated to the serum (s) free T4-index (r=0.20, p=0.01), and negatively to age (r=-0.18, p=0.02), but not significantly related to serum TSH or thyroid volume. Age correlated positively with thyroid volume (r=0.31, p < 0.001). In a regression analysis, s-free T4-index and age remained as the only determinants of the 24h and the 96 h RAIU. CONCLUSIONS: In patients with a symptomatic nodular goiter, serum T4 and age are the major determinants of the thyroid RAIU. A sub-normal serum TSH is not a marker of a compromised thyroid RAIU but reflects that the iodine is confined to a few 'hot spots'.


Subject(s)
Aging/physiology , Goiter, Nodular/metabolism , Iodine Radioisotopes/metabolism , Thyroid Gland/metabolism , Thyroid Gland/pathology , Thyrotropin/blood , Thyroxine/blood , Adult , Aged , Aged, 80 and over , Female , Goiter, Nodular/pathology , Goiter, Nodular/radiotherapy , Humans , Iodine Radioisotopes/therapeutic use , Middle Aged , Prospective Studies , Thyroid Function Tests , Thyroid Gland/radiation effects , Young Adult
3.
Acta Radiol ; 46(6): 569-75, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16334838

ABSTRACT

PURPOSE: To validate lymphatic mapping combined with sentinel lymph node biopsy as a staging procedure, and to evaluate the possible clinical implications of added oblique lymphoscintigraphy and/or tomography and test the intra- and interobserver reproducibility of lymphoscintigraphy. MATERIAL AND METHODS: Forty patients (17 F and 23 M, aged 32-90) with 24 T1 and 16 T2 squamous cell carcinoma of the oral cavity. Planar lymphoscintigraphy, emission and transmission tomography were performed. Detection and excision of the sentinel nodes were guided by a gamma probe. The sentinel nodes were step-sectioning and stained with hematoxylin and eosin and cytokeratin (CK 1). Histology and follow-up were used as "gold standard". Tumor location, number of sentinel lymph nodes, metastasis, and recurrences were registered. Two observers evaluated the lymphoscintigraphic images to assess the inter-rater agreement. RESULTS: Eleven (28%) patients were upstaged. The sentinel lymph node identification rate was 97.5%. Sentinel lymph node biopsy significantly differentiated between patients with or without lymph node metastasis (P = 0.001). Lymphatic mapping revealed 124 hotspots and 144 hot lymph nodes were removed by sentinel lymph node biopsy. Three patients developed a lymph node recurrence close to the primary tumor site during follow-up. Added oblique lymphoscintigraphic images and/or tomography revealed extra hotspots in 15/40 (38%) patients. In 4/40 (10%), extra contralateral hotspots were detected. CONCLUSION: Sentinel lymph node biopsy upstaged 28% of the patients. Sentinel lymph nodes close to the primary tumor were difficult to find. Added oblique planar images and/or tomographic images revealed extra clinical relevant hotspots in 38% of patients. Reproducibility proved excellent.


Subject(s)
Carcinoma, Squamous Cell/pathology , Mouth Neoplasms/pathology , Sentinel Lymph Node Biopsy , Tomography, Emission-Computed, Single-Photon , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/diagnostic imaging , Carcinoma, Squamous Cell/secondary , Coloring Agents , Female , Follow-Up Studies , Humans , Keratins/analysis , Lymph Nodes/diagnostic imaging , Lymph Nodes/pathology , Lymphatic Metastasis/pathology , Male , Middle Aged , Mouth Neoplasms/diagnostic imaging , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Observer Variation , Radiology, Interventional , Radiopharmaceuticals , Reproducibility of Results , Rhenium , Technetium Compounds
4.
Acta Radiol ; 46(5): 492-6, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16224924

ABSTRACT

PURPOSE: To compare sentinel lymph node biopsy, magnetic resonance imaging (MRI), Doppler ultrasonography, and palpation as staging tools in patients with T1/T2 N0 cancer of the oral cavity. MATERIAL AND METHODS: Forty consecutive patients were enrolled (17 F and 23 M, aged 32-90 years), 24 T1 and 16 T2 cN0 squamous cell carcinoma of the oral cavity. Palpation was carried out by two observers prior to inclusion. MRI, gray-scale and Doppler ultrasonography were performed. Lymphoscintigraphies were done after peritumoral injections of 99mTc labelled rheniumsulphide nanocolloid, followed by sentinel lymph node biopsy guided by a gamma probe and Patent Blue. Palpation, Doppler ultrasonography, MRI, and sentinel lymph node biopsy were compared to a combination of histopathology and follow-up. Diagnostic testing was performed using the x2 test. RESULTS: Histopathological examination revealed metastatic spread to the neck in 14 of 40 patients. One patient had bilateral neck disease. Sentinel lymph node biopsy and ultrasonography were performed in 80 neck sides of 40 patients and MRI in 70 neck sides (5 patients were claustrophobic). SN revealed suspicious lymph nodes in 12 necks, ultrasonography in 23 necks, and MRI in 9 necks. The positive predictive value of sentinel lymph node biopsy was 100%, ultrasonography 57%, and MRI 56%. The respective negative predictive values were 96%, 96%, and 85%. The sensitivity of sentinel lymph node biopsy 80% was comparable to ultrasonography 87%, but the sensitivity of MRI 36% was low. The specificities were 100%, 85%, and 93%, respectively. By combined sentinel lymph node biopsy and ultrasonography the overall sensitivity could have been 100%. CONCLUSION: Sentinel lymph node biopsy improved staging of patients with small N0 oral cancers. Combined sentinel lymph node biopsy and Doppler ultrasonography may further improve staging. MRI and simple palpation results were poor.


Subject(s)
Carcinoma, Squamous Cell/pathology , Magnetic Resonance Imaging/methods , Mouth Neoplasms/pathology , Mouth/diagnostic imaging , Mouth/pathology , Palpation/methods , Ultrasonography, Doppler/methods , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Chi-Square Distribution , Chlorides , Female , Humans , Male , Middle Aged , Mouth Neoplasms/mortality , Neoplasm Staging , Predictive Value of Tests , Prospective Studies , Radionuclide Imaging , Rhenium , Sensitivity and Specificity , Sentinel Lymph Node Biopsy/methods , Sulfides , Technetium
SELECTION OF CITATIONS
SEARCH DETAIL
...